Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
927.15
-19.95 (-2.11%) Zydus Lifesciences submits press release
Date: 12-04-2025Zydus Lifesciences has submitted a press release stating that Zydus received final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg.
The above information is a part of company’s filings submitted to BSE.